Cargando…
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356925/ https://www.ncbi.nlm.nih.gov/pubmed/32580478 http://dx.doi.org/10.3390/jcm9061950 |
_version_ | 1783558594652798976 |
---|---|
author | Conteduca, Vincenza Caffo, Orazio Scarpi, Emanuela Sepe, Pierangela Galli, Luca Fratino, Lucia Maines, Francesca Chiuri, Vincenzo Emanuele Santoni, Matteo Zanardi, Elisa Massari, Francesco Toma, Ilaria Lolli, Cristian Schepisi, Giuseppe Sbrana, Andrea Kinspergher, Stefania Cursano, Maria Concetta Casadei, Chiara Modonesi, Caterina Santini, Daniele Procopio, Giuseppe De Giorgi, Ugo |
author_facet | Conteduca, Vincenza Caffo, Orazio Scarpi, Emanuela Sepe, Pierangela Galli, Luca Fratino, Lucia Maines, Francesca Chiuri, Vincenzo Emanuele Santoni, Matteo Zanardi, Elisa Massari, Francesco Toma, Ilaria Lolli, Cristian Schepisi, Giuseppe Sbrana, Andrea Kinspergher, Stefania Cursano, Maria Concetta Casadei, Chiara Modonesi, Caterina Santini, Daniele Procopio, Giuseppe De Giorgi, Ugo |
author_sort | Conteduca, Vincenza |
collection | PubMed |
description | Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investigate the association between ADT and immune disorders, considering a potential role of androgens in the immune modulation. We retrospectively evaluated CRPC patients treated with abiraterone/enzalutamide between July 2011 and December 2018. We assessed the risk of developing immune alterations and their impact on outcome. We included 844 CRPC patients receiving AR-directed therapies, of whom 36 (4.3%) had autoimmune diseases and 47 (5.6%) second tumors as comorbidities. Median age was 70 years [interquartile range (IQR) = 63–75)]. We showed higher significant incidence of autoimmune diseases during their hormone sensitive status (p = 0.021) and the presence of autoimmune comorbidities before starting treatment with abiraterone/enzalutamide was significantly associated with worse overall survival (OS) (10.1 vs. 13.7 months, HR = 1.59, 95% CI 1.03–2.27, p = 0.038). In a multivariate analysis, the presence of autoimmune disorders was an independent predictor of OS (HR = 1.65, 95% CI 1.05–2.60, p = 0.031). In conclusion, CRPC patients with autoimmune alterations before starting AR-directed therapies may have worse prognosis. Further prospective studies are warranted to assess the role of immune modulation in the management of prostate cancer patients. |
format | Online Article Text |
id | pubmed-7356925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73569252020-07-22 Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy Conteduca, Vincenza Caffo, Orazio Scarpi, Emanuela Sepe, Pierangela Galli, Luca Fratino, Lucia Maines, Francesca Chiuri, Vincenzo Emanuele Santoni, Matteo Zanardi, Elisa Massari, Francesco Toma, Ilaria Lolli, Cristian Schepisi, Giuseppe Sbrana, Andrea Kinspergher, Stefania Cursano, Maria Concetta Casadei, Chiara Modonesi, Caterina Santini, Daniele Procopio, Giuseppe De Giorgi, Ugo J Clin Med Article Androgen deprivation therapy (ADT) is a cornerstone of treatment for prostate cancer and, in recent years, androgen receptor (AR)-targeted therapies (abiraterone and enzalutamide) have both been used for the treatment of castration-resistant prostate cancer (CRPC). In our study, we sought to investigate the association between ADT and immune disorders, considering a potential role of androgens in the immune modulation. We retrospectively evaluated CRPC patients treated with abiraterone/enzalutamide between July 2011 and December 2018. We assessed the risk of developing immune alterations and their impact on outcome. We included 844 CRPC patients receiving AR-directed therapies, of whom 36 (4.3%) had autoimmune diseases and 47 (5.6%) second tumors as comorbidities. Median age was 70 years [interquartile range (IQR) = 63–75)]. We showed higher significant incidence of autoimmune diseases during their hormone sensitive status (p = 0.021) and the presence of autoimmune comorbidities before starting treatment with abiraterone/enzalutamide was significantly associated with worse overall survival (OS) (10.1 vs. 13.7 months, HR = 1.59, 95% CI 1.03–2.27, p = 0.038). In a multivariate analysis, the presence of autoimmune disorders was an independent predictor of OS (HR = 1.65, 95% CI 1.05–2.60, p = 0.031). In conclusion, CRPC patients with autoimmune alterations before starting AR-directed therapies may have worse prognosis. Further prospective studies are warranted to assess the role of immune modulation in the management of prostate cancer patients. MDPI 2020-06-22 /pmc/articles/PMC7356925/ /pubmed/32580478 http://dx.doi.org/10.3390/jcm9061950 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Conteduca, Vincenza Caffo, Orazio Scarpi, Emanuela Sepe, Pierangela Galli, Luca Fratino, Lucia Maines, Francesca Chiuri, Vincenzo Emanuele Santoni, Matteo Zanardi, Elisa Massari, Francesco Toma, Ilaria Lolli, Cristian Schepisi, Giuseppe Sbrana, Andrea Kinspergher, Stefania Cursano, Maria Concetta Casadei, Chiara Modonesi, Caterina Santini, Daniele Procopio, Giuseppe De Giorgi, Ugo Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title | Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title_full | Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title_fullStr | Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title_full_unstemmed | Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title_short | Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy |
title_sort | immune modulation in prostate cancer patients treated with androgen receptor (ar)-targeted therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356925/ https://www.ncbi.nlm.nih.gov/pubmed/32580478 http://dx.doi.org/10.3390/jcm9061950 |
work_keys_str_mv | AT conteducavincenza immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT caffoorazio immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT scarpiemanuela immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT sepepierangela immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT galliluca immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT fratinolucia immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT mainesfrancesca immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT chiurivincenzoemanuele immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT santonimatteo immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT zanardielisa immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT massarifrancesco immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT tomailaria immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT lollicristian immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT schepisigiuseppe immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT sbranaandrea immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT kinspergherstefania immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT cursanomariaconcetta immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT casadeichiara immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT modonesicaterina immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT santinidaniele immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT procopiogiuseppe immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy AT degiorgiugo immunemodulationinprostatecancerpatientstreatedwithandrogenreceptorartargetedtherapy |